Sarepta Therapeutics,, Inc. - SRPT STOCK NEWS

Sarepta Therapeutics (NASDAQ:SRPT) has announced the recipients of its 7th Annual Route 79, The Duchenne Scholarship Program for the 2024-2025 academic year. 25 scholarships have been awarded, including 20 to individuals living with Duchenne muscular dystrophy and 5 to siblings of individuals with Duchenne. Each recipient will receive up to $5,000.

The program, created in 2018, recognizes exceptional individuals pursuing post-secondary education. Recipients are chosen by an independent committee based on community involvement, academic achievements, and personal essays. Since its inception, Sarepta has awarded nearly 140 scholarships through the Route 79 program.

Sarepta Therapeutics (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, announced equity awards granted on August 30, 2024 under its 2024 Employment Commencement Incentive Plan. Approved by the Compensation Committee of the Board of Directors, these awards serve as a material inducement for 20 new employees hired in August 2024. The awards include a total of 9,290 restricted stock units (RSUs), which will vest annually over four years, contingent on continued employment. Employees did not receive options to purchase shares of Sarepta's common stock. Sarepta focuses on developing treatments for Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs) and has over 40 programs in development.

Sarepta Therapeutics (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The event will take place on September 6, 2024, at 9:15 a.m. E.T. at the New York Marriott Marquis. Senior management will engage in a fireside chat, which will be webcast live on Sarepta's investor relations website and archived for 90 days.

Sarepta focuses on developing precision genetic medicines for rare diseases, particularly Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs). The company currently has over 40 programs in various stages of development, driven by its multi-platform Precision Genetic Medicine Engine in gene therapy, RNA, and gene editing.

Sarepta Therapeutics (NASDAQ: SRPT) reported strong financial results for Q2 2024, with net product revenues increasing 51% year-over-year to $360.5 million. ELEVIDYS contributed $121.7 million in revenue. The company achieved a GAAP net income of $6.5 million and a non-GAAP net income of $46.7 million. FDA expanded the ELEVIDYS label indication to include patients with Duchenne muscular dystrophy aged 4 and above.

2025 net product revenues are expected to be between $2.9 billion and $3.1 billion. The company will present further data on its SRP-9001 program at the 29th Annual Congress of the World Muscle Society in October 2024. The European Medicines Agency is reviewing the marketing authorization application for ELEVIDYS, with expected approval in 2025.

Roche, Sarepta's partner, will handle commercialization outside the U.S. Additionally, the FDA has granted Fast Track designation to SRP-9003 for limb-girdle muscular dystrophy Type 2E.

Sarepta Therapeutics (NASDAQ: SRPT), a leader in precision genetic medicine, announced equity awards granted as material inducement for employment to 19 new hires in July 2024.

On July 31, 2024, the Compensation Committee approved these awards under the 2024 Employment Commencement Incentive Plan, aligning with Nasdaq Listing Rule 5635(c)(4).

The awards consist of an aggregate of 14,495 restricted stock units (RSUs) that will vest annually over four years, contingent on continuous employment. No stock purchase options were granted.

Sarepta Therapeutics (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, will release its second quarter 2024 financial results on Wednesday, August 7, 2024, after the Nasdaq Global Market closes. The company will host a conference call at 4:30 p.m. E.T. to discuss the results. Investors can access the webcast live on Sarepta's website, with a replay available for one year. Phone participants must register online to receive dial-in details.

Sarepta focuses on developing treatments for Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), with over 40 programs in various stages of development. The company's pipeline is driven by its multi-platform Precision Genetic Medicine Engine in gene therapy, RNA, and gene editing.

Sarepta Therapeutics (NASDAQ: SRPT), a leader in precision genetic medicine for rare diseases, announced the granting of equity awards on June 28, 2024, as a material inducement for employment. These grants were approved under Sarepta's 2024 Employment Commencement Incentive Plan and in accordance with Nasdaq Listing Rule 5635(c)(4). The awards consist of options to purchase 5,100 shares of common stock and 19,980 restricted stock units (RSUs) distributed among 23 new employees hired in June 2024. The stock options have an exercise price of $158.00 per share, equal to the closing price on the grant date. Vesting schedules are set for four years for both options and RSUs, contingent on continued employment.

Sarepta Therapeutics announced an expanded FDA approval for ELEVIDYS (delandistrogene moxeparvovec-rokl) to treat Duchenne muscular dystrophy (DMD) in patients aged 4 and above. The FDA granted traditional approval for ambulatory patients and accelerated approval for non-ambulatory patients. The continued approval for non-ambulatory patients hinges on the results of a confirmatory trial. ELEVIDYS is contraindicated for patients with mutations in exon 8 and/or exon 9 of the DMD gene. Sarepta's ENVISION study aims to verify the clinical benefits of ELEVIDYS. The expansion represents a significant milestone for the Duchenne community and gene therapy.

Sarepta Therapeutics (NASDAQ:SRPT) announced on May 31, 2024, the issuance of equity awards as a material inducement for employment under Nasdaq Listing Rule 5635(c)(4). The awards were given to nine newly hired employees, granting a total of 8,975 restricted stock units (RSUs). The RSUs will vest in four equal installments annually over four years, subject to continuous employment. The awards were part of Sarepta's 2024 Employment Commencement Incentive Plan and approved by the Compensation Committee of the Board of Directors. No stock purchase options were granted.